Can DOTS control multidrug-resistant tuberculosis? (Q53861884)

21 May 2018

title

Can DOTS control multidrug-resistant tuberculosis? (English)

1 reference

21 May 2018

1 reference

multiple drug resistance

1 reference

2

Christopher Dye

1 reference

21 May 2018

Marcos A Espinal

1

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 April 2005

1 reference

21 May 2018

published in

The Lancet

1 reference

21 May 2018

volume

365

1 reference

21 May 2018

issue

9466

1 reference

21 May 2018

page(s)

1206-1209

1 reference

21 May 2018

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Tuberculosis epidemiology and control in Veracruz, Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Increasing transparency in partnerships for health--introducing the Green Light Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

The treatment of multidrug-resistant tuberculosis in Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2974788-7

7 January 2021

10.1016/S0140-6736(05)74788-7

Identifiers

DOI

1 reference

21 May 2018

1 reference

21 May 2018